Statistically significant and clinically meaningful improvements in mean ACQ-5 scores were reported at week 16 versus placebo ...

Phase 2 data presented at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting show deep and durable tumor regressions in heavily pre-treated melanoma patients, with a mild safety ...

Therapeutics presented new data from the ongoing REZOLVE-AD Phase 2b study in a late-breaking oral abstract presentation at the ...

Mechelen, Belgium; November 3, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will present new and updated data for CAR T-cell therapy candidate, GLPG51011, at the ...

SITC abstracts highlight updated immunogenicity results from the Phase 2 AMPLIFY-7P trial of ELI-002 7P and preclinical data on the use of ...

From silver nanofibers to smart, sensory-packed dressings, the next generation of wound-healing technology is blurring the ...

A collection of studies that chart how mammalian brain cells grow and differentiate is a ‘very valuable’ tool for ...

Bugra Demirel, through the means of his pro-business organization, Grow Tallahassee, blasted the poll out almost a week after ...

A specialist from Oman, located at the crossroads of Africa and Asia, explains that his nation serves as a microcosm when it ...

CHS-114 demonstrated robust and selective depletion of CCR8+ Tregs as well as favorable immune remodeling in tumor tissue from head and neck ...

These data were presented today during a late-breaking session at the American Heart Association (AHA) Scientific Sessions and published simultaneously in The New England Journal of Medicine (NEJM) in ...

Vancouver, Canada, November 4th, 2025, FinanceWire Equity Insider News Commentary – The precision medicine sector reached $119 billion in ...